CHAPTER 1 INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2 RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1. Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3 MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4 MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growing diagnostic applications of biomarkers
4.1.2. Increasing prevalence of cancer
4.1.3. Rising number of CROs and low cost of clinical trials in developing countries
4.1.4. Increasing R&D funding for pharma and biotech companies
4.2. Market Restraints & Challenges
4.2.1. High capital investments and low cost-benefit ratio
4.2.2. Technical issues related to sample collection and storage
4.3. Market Opportunities
4.3.1. Development of OMICS technology
4.3.2. Rising interdisciplinary systems biology approach
4.3.3. Paradigm shift towards personalized medicine for cancer treatments
CHAPTER 5 GLOBAL BIOMARKERS MARKET – BY PRODUCT
5.1. Introduction
5.2. Consumables
5.3. Services
5.4. Software
CHAPTER 6 GLOBAL BIOMARKERS MARKET – BY TYPE
6.1. Introduction
6.2. Safety Biomarkers
6.3. Efficacy Biomarkers
6.4. Validation Biomarkers
CHAPTER 7 GLOBAL BIOMARKERS MARKET – BY DISEASE INDICATION
7.1. Introduction
7.2. Cancer
7.3. Cardiovascular Disorders
7.4. Neurological Disorders
7.5. Immunological Disorders
7.6. Others
CHAPTER 8 GLOBAL BIOMARKERS MARKET – BY APPLICATION
8.1. Introduction
8.2. Diagnostics
8.3. Drug Discovery and Development
8.4. Personalized Medicine
8.5. Disease Risk Assessment
8.6. Others
CHAPTER 9 GLOBAL BIOMARKERS MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. Asia Pacific
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10 GLOBAL BIOMARKERS MARKET - COMPANY PROFILES
10.1. Qiagen N.V.
10.2. Perkinelmer, Inc.
10.3. Bio-Rad Laboratories, Inc.
10.4. MilliporeSigma
10.5. Enzo Biochem, Inc.
10.6. F. Hoffmann-La Roche Ltd.
10.7. Meso Scale Diagnostics, LLC
10.8. Signosis
10.9. Thermo Fisher Scientific Inc.
10.10. Siemens Healthineers AG
10.11. Epigenomics AG
10.12. Agilent Technologies, Inc.
10.13. Johnson & Johnson Services, Inc.
10.14. EKF Diagnostics Holdings, Inc.
CHAPTER 11 GLOBAL BIOMARKERS MARKET - COMPETITIVE LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12 MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13 APPENDIX
13.1. List of Tables
13.2. List of Figures
